Market Size
The global respules market reached USD 1.5 billion in 2022 and is projected to witness lucrative growth by reaching up to USD 2.5 billion by 2030. The market is expected to exhibit a CAGR of 6.1% during the forecast period 2024-2031. A respule is a little plastic container containing a liquid. The liquid is inserted into a nebulizer machine. The gadget produces a tiny mist of medication, which the patient inhales through a face mask or mouthpiece.
Respules are made with blow-fill-seal (BFS) technology, which is a manufacturing process for producing tiny (0.1mL) volume liquid-filled containers. Developed in Europe in the 1930s, it was introduced in the United States in the 1960s, but over the last 20 years, it has become more prevalent within the pharmaceutical industry and is now widely regarded as the superior form of aseptic processing by various medicine regulatory agencies, including the United States Food and Drug Administration (FDA), in the packaging of pharmaceutical and healthcare products.
Respules market is driven by various factors which help to drive the market in the forecast period like the rising incidence rate of chronic respiratory diseases, increasing demand for home healthcare devices and the rising geriatric population.
Market Scope
| Metrics | Details |
| CAGR | 6.1 % |
| Size Available for Years | 2021-2030 |
| Forecast Period | 2024-2031 |
| Data Availability | Value (USD ) |
| Segments Covered | Drug Type, Dosage & Strength, Distribution Channel and Region |
| Regions Covered | North America, Europe, Asia-Pacific, South America and Middle East & Africa |
| Fastest Growing Region | Asia-Pacific |
| Largest Region | North America |
| Report Insights Covered | Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and Acquisitions, New Type Launches, Growth Strategies, Revenue Analysis, Porter’s Analysis, Pricing Analysis, Regulatory Analysis, Supply-Chain Analysis, and Orthopedic Surgery key Insights. |
To Know more Insights Download Sample
Market Dynamics
Rise In the Incidence of Respiratory Disorders
The rise in the incidence of respiratory illnesses due to asthma, chronic obstructive pulmonary disease (COPD), and other respiratory disorders will drive the the market during forecast period Likewise Asthma, COPD and other respiratory disorders place a significant financial strain on the healthcare systems of numerous nations across the world.
For instance, according to the global strategy for diagnosis, management, and prevention of COPD study, the European Union spends around 6% of its overall healthcare expenditure (direct expenses) each year on addressing respiratory illnesses. Furthermore, COPD accounts for nearly 60% of the EU's overall expenditure on respiratory disorders each year, according to the paper.
Increasing Technological Advancements
Increasing technological advancements in the area of resources will significantly drive the market during the forecast period.
For instance, on January 25, 2023, synergy life science released Nebi, a revolutionary portable nebulizer.nebi is powered by a rechargeable battery and is tiny enough to carry in a pocket or handbag, making nebulizer therapies available on the road.
Nebi works with interchangeable, replaceable cartridges intended for specific uses, ailments and indications, providing helpful medications and therapies in the form of safe, cold water vapour constantly.
This portable nebulizer will first focus on cannabis, wellness and smoking cessation therapy, but it has enormous potential to address a wide range of treatment options across numerous sectors.
Side Effects Associated With the Devices
Users of nebulizers may face multiple adverse reactions. Wheezing, choking, or other breathing issues after using this drug, white spots or sores inside your mouth or on your lips, heartache, and other adverse effects. Severe reactions to nebulizer therapy are also possible and should be reported to the prescribing physician as soon as possible. Chest discomfort, redness, hives, swelling or trouble swallowing are all severe signs.
Market Segment Analysis
The global respules Market is segmented based on drug type, dosage & strength, distribution channel and region.
The Budesonide Drug Type Segment is Expected To Hold A Dominant Position in The Market Over The Forecast Period.
Budesonide drug type accounted for the biggest market stake accounting for approximately 39.1% of the Respules market share. Budesonide is used to treat asthma symptoms such as trouble breathing, chest tightness, wheezing and coughing. Budesonide powder for oral inhalation (Pulmicort Flexhaler) is prescribed for adults and children aged 6 and above.
For instance, Airsupra (albuterol and budesonide) inhalation aerosol has been approved by the FDA for the as-needed treatment or prevention of bronchoconstriction and to minimise the risk of asthma attacks in patients 18 years of age and older with asthma. Airsupra is a corticosteroid and albuterol (a beta-2 adrenergic agonist) combination.
It is the first inhaled corticosteroid (ICS) and short-acting beta-agonist combination to be authorised in the United States. Furthermore, Airsupra is the first ICS-containing medicine to be licenced in the United States as a relief therapy (rather than a controller) for asthma. To lower the risk of severe asthma episodes, the therapy helps to relax the muscles and reduce inflammation in the lung airways.
Source: DataM Intelligence Analysis (2023)
Market Geographical Share
North America Holds a Dominant Position in the Global Respules Market.
North America is estimated to hold about 41.4% of the total market share throughout the forecast period. A higher incidence of COPD and other chronic respiratory illnesses, as well as increased use of sophisticated portable ones in the area, have contributed to North America's larger market share.
For instance according to who report it is estimated that chronic obstructive pulmonary disease (COPD) is the third greatest cause of mortality globally, accounting for 3.23 million deaths in 2019. Low- and middle-income countries (lmic) account for about 90% of COPD fatalities among those under the age of 70.
Chronic obstructive pulmonary disease COPD is the world's seventh greatest cause of poor health (as assessed by disability-adjusted life years). Tobacco use is responsible for more than 70% of cases in high-income nations. tobacco use accounts for 30-40% of COPD cases in mics and home air pollution is a key risk factor.
Source: DataM Intelligence Analysis (2023)
Market Companies
The major global players in the market include Cipla, AstraZeneca, Sandoz International, Bio chemix Healthcare, Lupin, Amanta Healthcare, Lxir Medilabs, Intra Life, Cosmo Pharmaceuticals and Lunan Better Pharmaceutical.
COVID-19 Impact on Market
As the incidence of coronavirus infections increased, several nations had a major scarcity of ventilators and metre dosage inhalers. Due to the shortfall, there was an increase in demand for critical care equipment such as ventilators, pulse oximeters and others. Due to the scarcity of ventilators, healthcare providers were forced to rely on alternative breathing equipment such as nebulizers, Continuous Positive Airway Pressure (CPAP) and oxygen concentrators.
Russia-Ukraine War Impact Analysis
The Russia-Ukraine is estimated to have a minimal impact on the global Respules Market owing to the low prevalence and absence of key market players in this region.
The ongoing conflict between Russia and Ukraine has had substantial humanitarian and health consequences, including the possible influence on respiratory problems, which can lead to a variety of variables like as Supply Chain Disruption: Conflict can interrupt supply chains, making medical devices, particularly nebulizers, unavailable in impacted areas.
Infrastructure damage, transportation interruptions and trade restrictions may impede the import and distribution of nebulizers, potentially resulting in shortages or limited access to these devices.
Key Developments
- In Nov. 2022 First Public Booster Immunization in China using the World's First Inhaled COVID-19 Vaccine, Developed in Collaboration Between Aerogen and CanSino BIO. CanSino BIO (Tianjin, China) and Aerogen (Galway, Ireland) announced a development and commercial supply partnership for the inhaled delivery of CanSino BIO's Recombinant Novel Coronavirus Vaccine Convidicea Air TM using Aerogen's proprietary aerosol drug delivery technology.
- In Feb 2022 Glenmark signed a deal with AstraZeneca to market its Pulmicort Respules in Colombia. According to the terms of the agreement, AstraZeneca will continue to hold the registration for Pulmicort Respules and will manufacture the medicine. Glenmark will market the product in Colombia. This collaboration will assure continuing and expanded access to this critical medicine, providing much-needed therapeutic respite to Colombian asthma sufferers.
- In Jan 2023 Albuterol/Budesonide Rescue Medication Approved by the FDA for Asthma Exacerbations. The FDA has authorized the as-needed use of albuterol/budesonide (Air supra; AstraZeneca) to prevent and treat bronchoconstriction. Based on the results of the randomized, double-blind, multicenter, parallel-group, event-driven MANDALA and DENALI phase 3 studies, the medicine was authorized at a dosage of 180 mcg albuterol/160 mcg budesonide.
Why Purchase the Report?
- To visualize the global respules market segmentation based on drug type, dosage & strength, distribution channel and region, as well as understand key commercial assets and players.
- Identify commercial opportunities by analyzing trends and co-development.
- Excel data sheet with numerous data points of respules market-level with all segments.
- PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
- Product mapping available as Excel consisting of key products of all the major players.
The Global Respules Market Report Would Provide Approximately 53 Tables, 54 Figures and 195 Pages.
Target Audience 2023
- Manufacturers / Buyers
- Industry Investors/Investment Bankers
- Research Professionals
- Emerging Companies
